A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Janssen R&D Ireland
ClinicalTrials.gov Identifier:
NCT01323244
First received: March 24, 2011
Last updated: September 25, 2014
Last verified: September 2014

March 24, 2011
September 25, 2014
December 2011
January 2015   (final data collection date for primary outcome measure)
The proportion of participants with sustained viral response [ Time Frame: 12 weeks after planned end of treatment ] [ Designated as safety issue: Yes ]
The proportion of patients with sustained viral response (SVR) 24 weeks after the planned end of treatment [ Time Frame: 24 weeks after planned end of treatment ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT01323244 on ClinicalTrials.gov Archive Site
  • The proportion of participants with sustained viral response [ Time Frame: 24 weeks after planned end of treatment ] [ Designated as safety issue: Yes ]
  • Number of participants with HCV RNA level >1000 IU/mL [ Time Frame: Week 4 ] [ Designated as safety issue: No ]
  • Number of participants with viral breakthrough [ Time Frame: Through Week 48 ] [ Designated as safety issue: Yes ]
  • Number of participants with viral relapse [ Time Frame: Through Week 48 ] [ Designated as safety issue: Yes ]
  • Number of participants with normalized alanine aminotransferase levels [ Time Frame: Through Week 48 ] [ Designated as safety issue: No ]
  • Number of participants with on-treatment failure [ Time Frame: Through Week 48 ] [ Designated as safety issue: Yes ]
  • Number of participants affected by an adverse event [ Time Frame: Through Week 48 ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Not Provided
 
A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
A Phase III, Open-Label, Single Arm, Rollover Trial of TMC435 in Combination With Peginterferon Alpha-2A and Ribavirin for HCV Genotype-1 Infected Subjects Who Participated in the Placebo Group of a Phase II/III TMC435 Study, or Who Received DAA Treatment in a Tibotec-Sponsored Phase I Study.

The purpose of this study is to investigate the efficacy of a treatment with TMC435 in combination with peginterferon alfa-2a and ribavirin in patients who did not clear their hepatitis C infection with peginterferon alfa-2a and ribavirin alone within a previous trial conducted by Tibotec, or who participated in Tibotec trials in which antivirals directed against hepatitis C virus (HCV) were evaluated for short periods of time.

This is a roll over trial of TMC435 for patients with genotype-1 HCV infection who participated in the control (placebo; substance containing no active medication) group of a TMC435 trial or who received a treatment for up to 14 days with antivirals directed against HCV in a previous Tibotec trial. Patients in this study will receive TMC435 in combination with peginterferon alfa-2a (Pegasys) and ribavirin (Copegus) followed by peginterferon alfa-2a and ribavirin alone. The total treatment duration will be 24 or 48 weeks, depending on how the patients respond to treatment and which was their previous response to peginterferon alfa-2a and ribavirin alone. The study doctor will inform each patient about how to take their study medication and when they should stop taking it. After a patient stops taking study medication, they will contiue to come to the doctor's office for study visits until 24 weeks (in some cases up to 48 weeks) after end of treatment. The total duration of the study is 78 weeks (including screening). Patients will be monitored for safety throughout the study. Study assessments at each visit may include but are not limited to: blood and urine collection for testing, electrocardiogram (ECG) assessments (a measurement of the electrical activity of the heart) and physical examinations. TMC435 will be taken as an oral capsule of 150 mg once per day. Peginterferon (Pegasys) will be given as an injection of 180 µg once each week. Ribavirin will be taken as tablets (Copegus) twice each day and the dose will depend on patient's body weight.

Interventional
Phase 3
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Hepatitis C
Drug: TMC435
Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
Experimental: TMC435
TMC435 Type=exact number unit=mg number=150 form=capsule route=oral use once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
Intervention: Drug: TMC435
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
142
March 2015
January 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients who participated in the placebo arm of a TMC435 study who did not achieve undetectable HCV RNA levels at end of treatment or who relapsed within 1 year after end of treatment OR Patients who received short-term direct-acting antiviral therapy in a Tibotec-sponsored study.
  • Liver disease stage documented by liver biopsy is required within 3 years prior to screening unless contraindicated.

Exclusion Criteria:

  • Infection with human immunodeficiency virus.
  • Liver disease not related to hepatitic C infection.
  • Significant laboratory abnormalities or other active diseases.
  • Pregnant or planning to become pregnant.
  • Prematurely stopped medication in previous TMC435 study for non-compliance or for safety reasons.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
New Zealand,   United States,   Argentina,   Australia,   Austria,   Belgium,   Brazil,   Bulgaria,   Canada,   France,   Germany,   Israel,   Mexico,   Netherlands,   United Kingdom,   Poland,   Portugal,   Puerto Rico,   Romania,   Russian Federation,   Spain,   Ukraine
 
NCT01323244
CR017983, TMC435-TiDP16-C213
No
Janssen R&D Ireland
Janssen R&D Ireland
Not Provided
Study Director: Janssen R&D Ireland Clinical Trial Janssen R&D Ireland
Janssen R&D Ireland
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP